Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

Showing the 40 largest recruiting trials by target enrollment in Maine. Use the search field to focus on a condition or drug.

Recruiting NA 36,503 participants

Supraglottic Airway for Resuscitation Trial

Children's Hospital of Philadelphia

NCT07150923

Recruiting 5,000 participants

Cardiogenic Shock Working Group Registry

Tufts Medical Center

NCT04682483

Recruiting Phase 3 4,000 participants

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

University of Manitoba

NCT05848713

Recruiting NA 3,290 participants

Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy

University of Rochester

NCT06543446

Recruiting Phase 3 3,200 participants

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Icahn School of Medicine at Mount Sinai

NCT04045665

Recruiting NA 3,000 participants

Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders

University of Michigan

NCT05929703

Recruiting NA 2,700 participants

I-DECIDE After Bronchiolitis Hospitalization

Seattle Children's Hospital

NCT07243652

Recruiting Phase 3 2,400 participants

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Merck Sharp & Dohme

NCT06966700

Recruiting 2,150 participants

CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting

Corcym S.r.l

NCT05002543

Recruiting 2,020 participants

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Guardant Health

NCT05059444

Recruiting NA 1,440 participants

Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery

Unity Health Toronto

NCT04754022

Recruiting Phase 3 1,123 participants

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Merck Sharp & Dohme

NCT06952504

Recruiting NA 1,100 participants

IMPRoving Outcomes in Vascular DisEase - Aortic Dissection

Duke University

NCT06087029

Recruiting Phase 3 1,095 participants

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Genmab

NCT06191744

Recruiting NA 1,094 participants

Brain Oxygen Optimization in Severe TBI, Phase 3

University of Michigan

NCT03754114

Recruiting Phase 3 1,000 participants

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Olema Pharmaceuticals

NCT07085767

Recruiting NA 1,000 participants

Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors

Johns Hopkins University

NCT03803423

Recruiting Phase 2 920 participants

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

NCT04589845

Recruiting NA 842 participants

CTSN Embolic Protection Trial

Icahn School of Medicine at Mount Sinai

NCT06027788

Recruiting Phase 3 770 participants

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Merck Sharp & Dohme

NCT06824467

Recruiting Phase 3 714 participants

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Pfizer

NCT06758401

Recruiting Phase 3 700 participants

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

AstraZeneca

NCT07044336

Recruiting Phase 3 675 participants

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Merck Sharp & Dohme

NCT07190248

Recruiting Phase 3 614 participants

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Merck Sharp & Dohme

NCT06170788

Recruiting Phase 2 590 participants

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Bristol-Myers Squibb

NCT07063745

Recruiting Phase 3 558 participants

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

BioNTech SE

NCT07173751

Recruiting NA 550 participants

Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial

Medtronic Cardiovascular

NCT05378347

Recruiting Phase 3 520 participants

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

GlaxoSmithKline

NCT06679101

Recruiting 500 participants

Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study

Wake Forest University Health Sciences

NCT07215624

Recruiting Phase 4 500 participants

AWARE: Management of ADHD in Autism Spectrum Disorder

Daniel Coury

NCT05916339

Recruiting Phase 3 500 participants

Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

NYU Langone Health

NCT05591118

Recruiting Phase 3 466 participants

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Incyte Corporation

NCT07214779

Recruiting Phase 3 450 participants

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

Ivy Brain Tumor Center

NCT06388733

Recruiting NA 450 participants

Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)

Annetine Gelijns

NCT05051033

Recruiting Phase 3 410 participants

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

AVEO Pharmaceuticals

NCT06064877

Recruiting Phase 2 400 participants

Nectero EAST System Clinical Study

Nectero Medical

NCT06001918

Recruiting Phase 3 400 participants

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Day One Biopharmaceuticals

NCT05566795

Recruiting 400 participants

Immunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS)

MaineHealth

NCT02664831

Recruiting Phase 3 390 participants

Abatacept in Immune Checkpoint Inhibitor Myocarditis

Massachusetts General Hospital

NCT05335928

Recruiting Phase 2 375 participants

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Dana-Farber Cancer Institute

NCT04569747

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →